| Open Document File Size: 330,38 KBShare Result on Facebook
City Santos / San Francisco / Cambridge / / Company AEs / Astex Pharmaceuticals Inc. / / Facility Science University / Dana Farber Cancer Institute / Stable Disease / / IndustryTerm Cancer Therapeutics / suboptimal pharmaceutical properties / / MedicalCondition tumor / pain / vomiting / fatigue / lymphoma / stable disease / diarrhea / chills / GIST stable disease / significantly enhanced tumor / Active Against Gastrointestinal Stromal Tumors / inflammation / diplopia / progressive disease / rash / unresectable solid tumors / / MusicGroup Nausea / / Organization Mohammad Azab3 Arizona Cancer Center / Dana Farber Cancer Institute / Oregon Health & Science University / / Person Tammi Hipsher / Stuart Cattermole / Yong Hao / Aram Oganesian / Gillian Langford / Jennifer Culbertson / Stefan Dyla / Renee Hansen / Christopher Corless / / Technology pharmacokinetics / /
SocialTag |
Abstract # 105 AT13387, A Novel, Non-Ansamycin Inhibitor of Heat Shock Protein 90 is Active Against Gastrointestinal Stromal Tumors (GIST) Daruka Mahadevan1, Geoffrey Shapiro2, Sandra E. Kurtin1, James M. Cleary2, John F